$35 Million

Cabaletta Bio, Inc.

Lead Left Bookrunner, December 2022

Underwritten Offering

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform – encompassing chimeric antigen receptor T cells for autoimmunity (CARTA: CABA-201, a 4-1BB-containing CD19-CAR T) and Cabaletta Bio’s proprietary chimeric autoantibody receptor T cells (CAART: multiple candidates including DSG3-CAART for mucosal pemphigus vulgaris, MuSK-CAART for MuSK myasthenia gravis) – provides multiple opportunities to treat broad and challenging autoimmune diseases. Cabaletta Bio’s headquarters are located in Philadelphia, PA.

More Like This

Jan 2023
$150 Million

Senior Secured Term Loan

Sole Placement Agent and Exclusive Financial Advisor

View Details >
Dec 2022
Auctus logo

Werksarztzentrum Deutschland GmbH, a Portfolio Company of AUCTUS Capital Partners AG, was Acquired by a PE-Backed Strategic Buyer

Financial Advisor

View Details >
Dec 2022
$86.3 Million
Terns Pharmaceuticals logo

Follow-on Offering


View Details >